Protagonist Therapeutics, Inc. Announces Upsizing and Pricing of Underwritten Public Offering of 7,000,000 Shares of Common Stock

NEWARK, Calif., May 12, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of its common stock at a price to the public of…


Read Full Article